Drucker DJ, Erlich P, Asa SL, Brubaker PL
OMA recently sent letters to all 37 state governors of states that do not currently cover obesity medications, including GLP-1s, encouraging them to apply for the BALANCE Model
To ensure safety and compliance in drug compounding, you should: Confirm the pharmacy only uses semaglutide base API, not salt forms
Choose Ozempic if you prioritize maximum A1C reduction and want the strongest available glycemic control from a GLP-1 medication
Significantly more CagriSema participants achieved clinically meaningful weight loss thresholds of 5%, 10%, 15%, and 20% compared to placebo at all timepoints assessed
A compound can be widely discussed and still rest almost entirely on cell-culture and animal data, with little or no controlled human evidence